Source - RNS
RNS Number : 5900K
BioPharma Credit PLC
11 April 2018
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF EXTRAORDINARY GENERAL MEETING

 

On 16 March 2018, the Board of Directors of the Company published a circular with recommended proposals for Independent Shareholders to approve certain Related Party Transactions arising with respect to certain Shareholders in the Company may wish to participate in the proposed issue of Issue Shares pursuant to the Placing Programme and Offer which was announced on 8 March 2018 and launched under the Prospectus published on 14 March 2018 (the "Issue").

 

The Company is pleased to announce that, at the Extraordinary General Meeting held today, all resolutions were passed on a show of hands.

 

Resolution 1 (ordinary resolution): to approve the related party transaction involving Invesco Asset Management Limited and its associates.

 

Resolution 2 (ordinary resolution): to approve the related party transaction involving Prudential plc and its associates.

 

The proxy votes received in relation to these resolutions were as follows:

 

Resolutions

Votes For

Votes Against

Votes at Chairman's Discretion

Votes Withheld

 

 

 

 

 

Resolution 1

213,135,733

0

313,616

317,261,250

Resolution 2

393,138,463

0

313,616

137,258,520

 

 

A copy of the resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM

 

11 April 2018

 

 

Enquiries:

 

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

[email protected]

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist debt investor to the life sciences industry and joined the LSE in March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

 

LEI: 213800AV55PYXAS7SY24

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMSFWFSFFASEDL